CN101379192B - 治疗肿瘤的抗Met单克隆抗体及其片段和载体及相应产品 - Google Patents

治疗肿瘤的抗Met单克隆抗体及其片段和载体及相应产品 Download PDF

Info

Publication number
CN101379192B
CN101379192B CN2007800047097A CN200780004709A CN101379192B CN 101379192 B CN101379192 B CN 101379192B CN 2007800047097 A CN2007800047097 A CN 2007800047097A CN 200780004709 A CN200780004709 A CN 200780004709A CN 101379192 B CN101379192 B CN 101379192B
Authority
CN
China
Prior art keywords
cdr
seq
met
antibody
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800047097A
Other languages
English (en)
Chinese (zh)
Other versions
CN101379192A (zh
Inventor
保罗·玛丽亚·科莫格里奥
伊利萨·维格拉
西尔维亚·乔达诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
METHERESIS TRANSLATIONAL RESEARCH SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by METHERESIS TRANSLATIONAL RESEARCH SA filed Critical METHERESIS TRANSLATIONAL RESEARCH SA
Publication of CN101379192A publication Critical patent/CN101379192A/zh
Application granted granted Critical
Publication of CN101379192B publication Critical patent/CN101379192B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800047097A 2006-02-06 2007-02-05 治疗肿瘤的抗Met单克隆抗体及其片段和载体及相应产品 Active CN101379192B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06101345.4 2006-02-06
EP06101345 2006-02-06
PCT/EP2007/051066 WO2007090807A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Publications (2)

Publication Number Publication Date
CN101379192A CN101379192A (zh) 2009-03-04
CN101379192B true CN101379192B (zh) 2013-07-31

Family

ID=36616994

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800047097A Active CN101379192B (zh) 2006-02-06 2007-02-05 治疗肿瘤的抗Met单克隆抗体及其片段和载体及相应产品

Country Status (21)

Country Link
US (2) US8388958B2 (cg-RX-API-DMAC7.html)
EP (2) EP2192188A1 (cg-RX-API-DMAC7.html)
JP (1) JP5306828B2 (cg-RX-API-DMAC7.html)
KR (1) KR101429297B1 (cg-RX-API-DMAC7.html)
CN (1) CN101379192B (cg-RX-API-DMAC7.html)
AT (1) ATE514715T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007213804B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0707480A8 (cg-RX-API-DMAC7.html)
CA (1) CA2638889C (cg-RX-API-DMAC7.html)
CY (1) CY1111884T1 (cg-RX-API-DMAC7.html)
DK (1) DK1981981T3 (cg-RX-API-DMAC7.html)
EA (1) EA015580B1 (cg-RX-API-DMAC7.html)
ES (1) ES2368864T3 (cg-RX-API-DMAC7.html)
IL (1) IL192879A (cg-RX-API-DMAC7.html)
MX (1) MX2008009833A (cg-RX-API-DMAC7.html)
PL (1) PL1981981T3 (cg-RX-API-DMAC7.html)
PT (1) PT1981981E (cg-RX-API-DMAC7.html)
SG (2) SG169383A1 (cg-RX-API-DMAC7.html)
SI (1) SI1981981T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007090807A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806559B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) * 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
LT3904391T (lt) 2010-03-10 2024-10-10 Genmab A/S Monokloniniai antikūnai prieš c-met
WO2011125458A1 (ja) 2010-04-02 2011-10-13 富士レビオ株式会社 抗癌剤の効果の診断用マーカー
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
US9150655B2 (en) * 2010-09-03 2015-10-06 Academia Sinica Anti-C-met antibody and methods of use thereof
US8637027B2 (en) 2010-11-03 2014-01-28 Argen-X B.V. Anti c-Met antibodies
SI2500036T1 (sl) * 2011-03-18 2014-09-30 Metheresis Translational Research Sa Met inhibitorji za izboljĺ anje uäśinkovitosti obsevanja
JP2014530201A (ja) 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
CN104066748A (zh) 2011-11-21 2014-09-24 霍夫曼-拉罗奇有限公司 抗c-met抗体的纯化
WO2013079973A1 (en) * 2011-12-02 2013-06-06 Di Cara Danielle Marie Antibodies against hgf - receptor and uses
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
US10377827B2 (en) * 2012-06-21 2019-08-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
CA2961323C (en) 2014-09-16 2021-11-30 Symphogen A/S Anti-met antibodies and compositions
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
CN107613974B (zh) * 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
GB201611123D0 (en) 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
KR102443619B1 (ko) * 2016-09-29 2022-09-14 미쓰비시 타나베 파마 코퍼레이션 cMET 단일클론 결합제, 이의 약물 접합체 및 이의 용도
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
CA3094827A1 (en) * 2018-03-28 2019-10-03 Mitsubishi Tanabe Pharma Corporation Drug conjugates of cmet monoclonal binding agents, and uses thereof
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
TW202448953A (zh) 2023-06-01 2024-12-16 法商皮爾法伯製藥公司 用於腫瘤及轉移之治療的基於沉默抗體的抗met建構物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130193A (zh) * 1994-11-18 1996-09-04 分子免疫中心 识别表皮生长因子受体(egf-r)的人源化和嵌合体的单克隆抗体及其诊断和治疗用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1130193A (zh) * 1994-11-18 1996-09-04 分子免疫中心 识别表皮生长因子受体(egf-r)的人源化和嵌合体的单克隆抗体及其诊断和治疗用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A Petrelli et al.Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity.《PNAS》.2006,第103卷(第13期),摘要、5091页左栏倒数第2段至5095页右栏第2段. *
G Cortesina et al.Staging of head and neck squamous cell carcinoma using the met oncogene product as marker of tumor cells in lymphnode metastases.《Int.J.Cancer》.2000,第89卷(第3期),摘要、286页右栏倒数第1段至288页左栏第1段、图2. *

Also Published As

Publication number Publication date
KR20090013745A (ko) 2009-02-05
US20120134996A1 (en) 2012-05-31
IL192879A0 (en) 2009-02-11
AU2007213804A8 (en) 2008-08-28
PL1981981T3 (pl) 2011-11-30
AU2007213804B2 (en) 2012-12-13
EP1981981B1 (en) 2011-06-29
BRPI0707480A2 (pt) 2011-05-03
JP2009526010A (ja) 2009-07-16
US20090285807A1 (en) 2009-11-19
DK1981981T3 (da) 2011-09-26
MX2008009833A (es) 2008-10-23
CA2638889C (en) 2015-06-02
US8729043B2 (en) 2014-05-20
EP1981981A1 (en) 2008-10-22
PT1981981E (pt) 2011-10-04
ZA200806559B (en) 2012-12-27
WO2007090807A1 (en) 2007-08-16
EA015580B1 (ru) 2011-10-31
CA2638889A1 (en) 2007-08-16
US8388958B2 (en) 2013-03-05
IL192879A (en) 2014-02-27
BRPI0707480A8 (pt) 2022-11-08
SG169383A1 (en) 2011-03-30
SI1981981T1 (sl) 2012-01-31
EA200870234A1 (ru) 2009-02-27
CY1111884T1 (el) 2015-11-04
AU2007213804A1 (en) 2007-08-16
CN101379192A (zh) 2009-03-04
SG169382A1 (en) 2011-03-30
JP5306828B2 (ja) 2013-10-02
EP2192188A1 (en) 2010-06-02
ATE514715T1 (de) 2011-07-15
ES2368864T3 (es) 2011-11-23
KR101429297B1 (ko) 2014-08-12

Similar Documents

Publication Publication Date Title
CN101379192B (zh) 治疗肿瘤的抗Met单克隆抗体及其片段和载体及相应产品
ES2929276T3 (es) Constructos de anticuerpo para CDH19 y CD3
CN101014625B (zh) 新抗-igf-ir抗体及其用途
KR101683884B1 (ko) 항-ＥｐＣＡＭ 항체 및 이의 용도
AU2013306390B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
US8841424B2 (en) Humanized AXL antibodies
US20250084160A1 (en) Antibodies targeting cdh19 for melanoma
US20130164300A1 (en) Monoclonal antibodies and fragment thereof directed against the human anti-mullerian hormone type ii receptor (amhr-ii)
US20110212091A1 (en) Materials and methods for inhibiting cancer cell invasion
CN104072614A (zh) 抗-αvβ6 抗体及其用途
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
AU2005224081A1 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2023016509A1 (zh) 抑制肿瘤细胞转移的药物及其用途
US7642341B2 (en) Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
US20240228629A1 (en) Anti-domain iv egfr antibodies and uses thereof
KR20120123619A (ko) 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
WO2013173745A1 (en) Monoclonal antibodies to macrophage stimulating protein
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20220221

Address after: Basel, Switzerland

Patentee after: Vertical biology Co.,Ltd.

Address before: Torino

Patentee before: Medex precision Pharmaceutical Co.,Ltd.

Effective date of registration: 20220221

Address after: Torino

Patentee after: Medex precision Pharmaceutical Co.,Ltd.

Address before: Lugano, Switzerland

Patentee before: METHERESIS TRANSLATIONAL RESEARCH S.A.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20241127

Address after: Laval, France

Patentee after: PIERRE FABRE MEDICAMENT

Country or region after: France

Address before: Basel, SUI

Patentee before: Vertical biology Co.,Ltd.

Country or region before: Switzerland

TR01 Transfer of patent right